◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Helix BioPharma Corp.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q4 2025Oct 31, 2025 Q3 2025Jul 31, 2025 Q2 2025Apr 30, 2025 Q1 2025Jan 31, 2025 Q4 2024Oct 31, 2024
Total Revenue 0.00 -- 0.00 0.00 0.00
Operating Revenue 0.00 -- 0.00 0.00 0.00
Selling General And Administration 537,000 475,000 647,000 444,000 273,000
General And Administrative Expense 537,000 475,000 647,000 444,000 273,000
Research And Development 391,000 -- 906,000 848,000 1.3M
Other Operating Expenses -- -- 541,000 422,000 245,000
Operating Expense 928,000 -- 1.6M 1.3M 1.6M
Operating Income -928,000 -- -1.6M -1.3M -1.6M
EBIT -997,000 -- -1.5M -1.4M -1.3M
Interest Expense 11,000 -- 1,000 3,000 1,000
Interest Expense Non Operating 11,000 -- 1,000 3,000 1,000
Interest Income 2,000 -- 8,000 2,000 7,000
Interest Income Non Operating 2,000 -- 8,000 2,000 7,000
Net Interest Income -9,000 -- 7,000 -1,000 6,000
Other Income Expense -71,000 -- 2,000 -82,000 252,000
Other Non Operating Income Expenses -- -- -- -- 268,000
Special Income Charges 0.00 -- -2,000 13,000 6,000
Gain On Sale Of Security -71,000 -- 4,000 -95,000 -22,000
Pretax Income -1.0M -- -1.5M -1.4M -1.3M
Tax Effect Of Unusual Items 0.00 -- 0.00 0.00 0.00
Net Income From Continuing And Discontinued Operation -1.0M -- -1.5M -1.4M -1.3M
Net Income From Continuing Operation Net Minority Interest -1.0M -- -1.5M -1.4M -1.3M
Net Income Including Noncontrolling Interests -1.0M -- -1.5M -1.4M -1.3M
Net Income Common Stockholders -1.0M -- -1.5M -1.4M -1.3M
Net Income -1.0M -- -1.5M -1.4M -1.3M
EBITDA -995,000 -- -1.5M -1.4M -1.3M
Normalized EBITDA -924,000 -- -1.5M -1.3M -1.3M
Reconciled Depreciation 2,000 -- 3,000 2,000 4,000
Basic EPS -0.01 -- -0.03 -0.03 -0.03
Diluted EPS -0.01 -- -0.03 -0.03 -0.03
Basic Average Shares 75.9M -- 53.0M 50.1M 49.0M
Diluted Average Shares 75.9M -- 53.0M 50.1M 49.0M
Total Unusual Items -71,000 -- 2,000 -82,000 -16,000
Total Unusual Items Excluding Goodwill -71,000 -- 2,000 -82,000 -16,000
Tax Rate For Calcs 0.00 -- 0.00 0.00 0.00
Normalized Income -937,000 -- -1.5M -1.3M -1.3M
Diluted NI Availto Com Stockholders -1.0M -- -1.5M -1.4M -1.3M
Gain On Sale Of Ppe 0.00 -- -2,000 13,000 6,000
Net Income Continuous Operations -1.0M -- -1.5M -1.4M -1.3M
Net Non Operating Interest Income Expense -9,000 -- 7,000 -1,000 6,000
Other Gand A 401,000 333,000 541,000 422,000 245,000
Other Special Charges -- -- -- -- -268,000
Salaries And Wages 136,000 -- 106,000 22,000 28,000
Total Expenses 928,000 -- 1.6M 1.3M 1.6M
Line Item Q4 2025Oct 31, 2025 Q3 2025Jul 31, 2025 Q2 2025Apr 30, 2025 Q1 2025Jan 31, 2025 Q4 2024Oct 31, 2024
Cash And Cash Equivalents 498,000 -- 715,000 2.0M 228,000
Cash Cash Equivalents And Short Term Investments 498,000 -- 715,000 2.0M 228,000
Cash Financial 498,000 -- 715,000 2.0M 228,000
Receivables 177,000 -- 287,000 236,000 176,000
Prepaid Assets -- -- -- -- --
Current Assets 675,000 -- 1.0M 2.2M 404,000
Gross PPE 1.2M -- 1.2M 1.2M 1.3M
Accumulated Depreciation -1.2M -- -1.2M -1.2M -1.3M
Net PPE 2,000 -- 7,000 10,000 10,000
Goodwill And Other Intangible Assets 18.4M -- -- -- --
Total Non Current Assets 18.4M -- 7,000 10,000 10,000
Total Assets 19.1M -- 1.0M 2.2M 414,000
Current Debt 352,000 -- -- -- --
Current Debt And Capital Lease Obligation 352,000 -- -- -- --
Accounts Payable 2.1M -- 1.8M 1.4M 988,000
Payables 2.1M -- 1.8M 1.4M 988,000
Payables And Accrued Expenses 2.6M -- 2.4M 2.3M 1.8M
Current Accrued Expenses 586,000 -- 617,000 821,000 790,000
Current Liabilities 3.0M -- 2.4M 2.3M 1.8M
Total Non Current Liabilities Net Minority Interest 0.00 -- 0.00 0.00 0.00
Total Liabilities Net Minority Interest 3.0M -- 2.4M 2.3M 1.8M
Common Stock 180.8M -- 161.4M 161.3M 158.6M
Capital Stock 180.8M -- 161.4M 161.3M 158.6M
Additional Paid In Capital 48.3M -- 48.3M 47.3M 46.8M
Retained Earnings -216.9M -- -214.9M -213.4M -212.0M
Common Stock Equity 16.1M -- -1.4M -19,000 -1.4M
Stockholders Equity 16.1M -- -1.4M -19,000 -1.4M
Total Equity Gross Minority Interest 16.1M -- -1.4M -19,000 -1.4M
Total Capitalization 16.1M -- -1.4M -19,000 -1.4M
Net Tangible Assets -2.3M -- -1.4M -19,000 -1.4M
Tangible Book Value -2.3M -- -1.4M -19,000 -1.4M
Working Capital -2.3M -- -1.4M -29,000 -1.4M
Invested Capital 16.4M -- -1.4M -19,000 -1.4M
Total Debt 352,000 -- -- -- --
Share Issued 76.4M -- 53.1M 53.0M 49.0M
Ordinary Shares Number 76.4M -- 53.1M 53.0M 49.0M
Leases 0.00 -- 0.00 0.00 0.00
Machinery Furniture Equipment 105,000 -- 105,000 106,000 104,000
Other Equity Interest 3.9M -- 3.9M 4.8M 5.2M
Other Properties 1.1M -- 1.1M 1.1M 1.2M
Other Receivables 153,000 -- 270,000 217,000 155,000
Properties 0.00 -- 0.00 0.00 0.00
Taxes Receivable 24,000 -- 17,000 19,000 21,000
Line Item Q4 2025Oct 31, 2025 Q3 2025Jul 31, 2025 Q2 2025Apr 30, 2025 Q1 2025Jan 31, 2025 Q4 2024Oct 31, 2024
Operating Cash Flow -1.2M -- -1.4M -940,000 -861,000
Cash Flow From Continuing Operating Activities -1.2M -- -1.4M -940,000 -861,000
Depreciation And Amortization 2,000 -- 3,000 2,000 4,000
Depreciation Amortization Depletion 2,000 -- 3,000 2,000 4,000
Stock Based Compensation 0.00 -- 60,000 35,000 62,000
Deferred Tax 15,000 -- -- -- 0.00
Deferred Income Tax 15,000 -- -- -- 0.00
Change In Working Capital -306,000 -- 102,000 302,000 675,000
Changes In Account Receivables 67,000 -- 2,000 2,000 18,000
Change In Receivables 67,000 -- 2,000 2,000 18,000
Change In Payables And Accrued Expense -458,000 -- 153,000 362,000 476,000
Change In Other Current Liabilities -- -- 0.00 0.00 0.00
Other Non Cash Items 4,000 -- 0.00 0.00 -268,000
Capital Expenditure -- -- -- -- --
Purchase Of PPE -- -- 0.00 -2,000 0.00
Net PPE Purchase And Sale 0.00 -- 0.00 9,000 8,000
Investing Cash Flow 0.00 -- 0.00 9,000 8,000
Cash Flow From Continuing Investing Activities 0.00 -- 0.00 9,000 8,000
Repayment Of Debt -- -- -- -- --
Net Issuance Payments Of Debt -- -- -- -- --
Issuance Of Capital Stock 1.7M -- 100,000 2.7M 0.00
Net Common Stock Issuance 1.7M -- 100,000 2.7M 0.00
Financing Cash Flow 1.7M -- 100,000 2.7M 0.00
Cash Flow From Continuing Financing Activities 1.7M -- 100,000 2.7M 0.00
Effect Of Exchange Rate Changes -- -- 0.00 0.00 0.00
Changes In Cash 433,000 -- -1.3M 1.8M -853,000
Beginning Cash Position 65,000 -- 2.0M 228,000 1.1M
End Cash Position 498,000 -- 715,000 2.0M 228,000
Free Cash Flow -1.2M -- -1.4M -942,000 -861,000
Interest Paid Supplemental Data 1,000 -- -- -- 0.00
Change In Prepaid Assets 85,000 -- -53,000 -62,000 181,000
Common Stock Issuance 1.7M -- 100,000 2.7M 0.00
Depreciation 2,000 -- 3,000 2,000 4,000
Gain Loss On Sale Of PPE 0.00 -- 2,000 -13,000 -6,000
Net Foreign Currency Exchange Gain Loss 71,000 -- -4,000 109,000 8,000
Net Income From Continuing Operations -1.0M -- -1.5M -1.4M -1.3M
Net Short Term Debt Issuance -- -- -- -- --
Operating Gains Losses 71,000 -- -2,000 96,000 2,000
Sale Of PPE 0.00 -- 0.00 11,000 8,000
Short Term Debt Payments -- -- -- -- --
NEWS
Loading news...
TRENDING
Loading...